Dada Nexus, Salarius Pharmaceuticals and 3 Stocks To Watch Heading Into Monday is an article about some companies that people might want to pay attention to because they did something important or interesting recently. Some of these companies might make more money than others, and this can affect how much their stocks are worth. People who own stocks in these companies hope that the stock prices will go up so they can sell them for a profit. The article also talks about what some experts think will happen with these stocks in the future. Read from source...

1. The title of the article is misleading and does not reflect the content. It implies that there are only three stocks to watch, but in reality, the article mentions two stocks and one company (Dada Nexus) that is expected to report quarterly earnings. A more accurate title would be "Dada Nexus And Salarius Pharmaceuticals: Two Stocks To Watch Heading Into Monday".
2. The use of the term "Wall Street expects" without specifying a source or a methodology behind the expectations is vague and unreliable. It creates a false impression that there is some consensus among experts or analysts regarding the earnings and revenue figures, when in fact it may just be based on rumors, guesses, or estimates from online platforms like Benzinga Pro.
3. The reporting of Dada Nexus' share price gain in after-hours trading without providing any context or explanation is irrelevant and confusing for the reader. It does not indicate whether this is a significant movement or a normal fluctuation, nor does it offer any reason why the stock might be gaining value. Additionally, it creates a false impression that Dada Nexus is performing well or has positive news, when in fact the article may have negative information about its earnings and revenue figures.
4. The reporting of Salarius Pharmaceuticals' net loss without providing any context or explanation is misleading and unfair. It does not indicate whether this is an improvement from the previous year or a worsening situation, nor does it offer any reason why the stock might be gaining value despite the reported loss. Additionally, it creates a false impression that Salarius Pharmaceuticals is a bad investment or has negative news, when in fact the article may have positive information about its earnings and revenue figures.
5. The use of emotional language such as "jumped" to describe the stock price movements is unprofessional and inflammatory. It implies that there is some sudden or unexpected change in the market sentiment, when in fact it may just be a normal reaction to the earnings and revenue figures reported by both companies.

Possible responses from AI:

- Based on my analysis of the article, I suggest you consider buying DADA and selling Salarius Pharmaceuticals. The reason is that DADA has a positive earnings surprise and strong revenue growth potential, while Salarius Pharmaceuticals has a narrowed loss but still faces uncertainty in its clinical trials. Additionally, I recommend you diversify your portfolio by investing in other sectors such as real estate, technology or health care. This will help you reduce the volatility and risk of your stock picks.